About HeartBeam

HeartBeam has developed a 3D-vector electrocardiogram (VECG) platform that synthesizes a 12-lead ECG using a portable, credit card-sized device. This technology enables patients to capture heart signals from three distinct directions, allowing physicians to detect non-life-threatening arrhythmias that traditional at-home monitors cannot identify.

```xml <problem> Traditional 12-lead electrocardiograms (ECGs) require trained healthcare professionals and are impractical for frequent at-home use, hindering timely detection of non-life-threatening arrhythmias. Existing at-home monitors often lack the fidelity to capture comprehensive heart signals, leading to missed diagnoses and delayed care. </problem> <solution> HeartBeam offers a compact, patient-friendly ECG system designed to synthesize a 12-lead ECG from anywhere. The system comprises a credit card-sized device, the HeartBeam AIMIGo, and a patient mobile app that guides users through the recording process. The device captures heart signals from three distinct directions, enabling physicians to detect a broader range of arrhythmias compared to conventional at-home monitors. Recordings are transmitted to the HeartBeam cloud, where on-call physicians can review the data and facilitate timely follow-up with patients. </solution> <features> - Credit card-sized HeartBeam AIMIGo device for on-the-go ECG recordings - Patient mobile app with step-by-step guidance for accurate data capture - High-fidelity ECG approach capturing heart signals from three distinct directions - Wireless data transmission to the HeartBeam cloud for physician review - Capability to synthesize a 12-lead ECG (Note: 12-lead synthesis software not cleared by the FDA and not available for sale in the United States) </features> <target_audience> The primary target audience includes individual patients seeking convenient at-home heart monitoring, as well as healthcare providers looking to improve arrhythmia detection and patient care. </target_audience> ```

What does HeartBeam do?

Where is HeartBeam located?

HeartBeam is based in Santa Clara, Cuba.

When was HeartBeam founded?

HeartBeam was founded in 2015.

How much funding has HeartBeam raised?

HeartBeam has raised 23200000.

Location

Santa Clara, Cuba

Founded

2015

Funding

23200000

Employees

31 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

HeartBeam

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

heartbeam.com 2K+

Crunchbase

Founded 2015 – Santa Clara, Cuba

Funding

Estimated Funding

$20M+

Team (30+)

No team information available.

Company Description

Problem

Traditional 12-lead electrocardiograms (ECGs) require trained healthcare professionals and are impractical for frequent at-home use, hindering timely detection of non-life-threatening arrhythmias. Existing at-home monitors often lack the fidelity to capture comprehensive heart signals, leading to missed diagnoses and delayed care.

Solution

HeartBeam offers a compact, patient-friendly ECG system designed to synthesize a 12-lead ECG from anywhere. The system comprises a credit card-sized device, the HeartBeam AIMIGo, and a patient mobile app that guides users through the recording process. The device captures heart signals from three distinct directions, enabling physicians to detect a broader range of arrhythmias compared to conventional at-home monitors. Recordings are transmitted to the HeartBeam cloud, where on-call physicians can review the data and facilitate timely follow-up with patients.

Features

Credit card-sized HeartBeam AIMIGo device for on-the-go ECG recordings

Patient mobile app with step-by-step guidance for accurate data capture

High-fidelity ECG approach capturing heart signals from three distinct directions

Wireless data transmission to the HeartBeam cloud for physician review

Capability to synthesize a 12-lead ECG (Note: 12-lead synthesis software not cleared by the FDA and not available for sale in the United States)

Target Audience

The primary target audience includes individual patients seeking convenient at-home heart monitoring, as well as healthcare providers looking to improve arrhythmia detection and patient care.